What factors do you consider when sequencing bispecific T-cell engaging antibodies and CAR T-cell therapies for the treatment of follicular lymphoma?  

I always choose CART first. It is unclear how much bispecific antibodies will affect CART manufacturing or T-cell fitness. There is a good date of efficacy post CART relapsed with bispecific antibodies.